[go: up one dir, main page]

NO20040122L - Fremgangsmåte for fremstilling av aminopyrimidinforbindelser samt pyrimidinforbindelser - Google Patents

Fremgangsmåte for fremstilling av aminopyrimidinforbindelser samt pyrimidinforbindelser

Info

Publication number
NO20040122L
NO20040122L NO20040122A NO20040122A NO20040122L NO 20040122 L NO20040122 L NO 20040122L NO 20040122 A NO20040122 A NO 20040122A NO 20040122 A NO20040122 A NO 20040122A NO 20040122 L NO20040122 L NO 20040122L
Authority
NO
Norway
Prior art keywords
compounds
preparation
aminopyrimidine
pyrimidine
pyrimidine compounds
Prior art date
Application number
NO20040122A
Other languages
English (en)
Other versions
NO326173B1 (no
Inventor
Akio Matsushita
Mizuho Oda
Yasuhiro Kawachi
Jun-Ichi Chika
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO20040122L publication Critical patent/NO20040122L/no
Publication of NO326173B1 publication Critical patent/NO326173B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20040122A 2001-07-13 2004-01-12 Fremgangsmate for fremstilling av aminopyrimidinforbindelser samt pyrimidinforbindelser NO326173B1 (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2001213417 2001-07-13
JP2001213418 2001-07-13
JP2001310900 2001-10-09
JP2001360339 2001-11-27
JP2002007015 2002-01-16
JP2002042076 2002-02-19
PCT/JP2002/007129 WO2003006439A1 (en) 2001-07-13 2002-07-12 Preparation of aminopyrimidine compounds

Publications (2)

Publication Number Publication Date
NO20040122L true NO20040122L (no) 2004-01-12
NO326173B1 NO326173B1 (no) 2008-10-13

Family

ID=27554967

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040122A NO326173B1 (no) 2001-07-13 2004-01-12 Fremgangsmate for fremstilling av aminopyrimidinforbindelser samt pyrimidinforbindelser

Country Status (27)

Country Link
US (4) US7304156B2 (no)
EP (1) EP1417180B1 (no)
JP (2) JP4359141B2 (no)
KR (1) KR100888408B1 (no)
CN (2) CN1301977C (no)
AR (2) AR034772A1 (no)
AT (1) ATE349431T1 (no)
AU (1) AU2002318041B2 (no)
BR (1) BR0211072A (no)
CA (1) CA2453505C (no)
CO (1) CO5560574A2 (no)
CY (1) CY1107551T1 (no)
DE (1) DE60217126T2 (no)
DK (1) DK1417180T3 (no)
EG (1) EG24848A (no)
ES (1) ES2278032T3 (no)
HU (1) HUP0401248A3 (no)
IL (2) IL159741A0 (no)
IS (1) IS2399B (no)
MX (1) MXPA04000322A (no)
MY (1) MY133579A (no)
NO (1) NO326173B1 (no)
NZ (1) NZ531033A (no)
PL (1) PL366831A1 (no)
PT (1) PT1417180E (no)
SI (1) SI1417180T1 (no)
WO (1) WO2003006439A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
IL159741A0 (en) * 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
BR0317313A (pt) 2002-12-16 2005-11-08 Astrazeneca Uk Ltd Processo para a preparação de um composto, e, composto
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
WO2007125547A2 (en) 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
SI2086945T1 (sl) 2006-10-09 2016-05-31 Msn Laboratories Private Limited Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
CN101323597B (zh) * 2007-06-11 2012-09-05 安徽省庆云医药化工有限公司 4-(4-氟苯基)-6-异丙基-2-(n-甲基-n-甲磺酰氨基)嘧啶-5-甲醛的制备方法
CN101376647B (zh) * 2007-08-31 2010-12-08 中山奕安泰医药科技有限公司 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法
WO2009150668A1 (en) * 2008-06-13 2009-12-17 Delhi University Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
EP2423195A1 (en) 2010-07-26 2012-02-29 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
CN101955463B (zh) * 2010-08-04 2012-01-04 重庆博腾制药科技股份有限公司 瑞舒伐他汀钙中间体的制备方法
CN102584717B (zh) * 2011-01-17 2014-12-10 浙江九洲药业股份有限公司 用于制备罗苏伐他汀的中间体及相关制备方法和用途
WO2013185309A1 (zh) * 2012-06-13 2013-12-19 上海迪赛诺药业有限公司 瑞舒伐他汀钙及其中间体的制备方法
CN103483269B (zh) * 2012-06-13 2016-04-27 上海迪赛诺药业有限公司 瑞舒伐他汀钙及其中间体的制备方法
CN103864697A (zh) * 2012-12-11 2014-06-18 润泽制药(苏州)有限公司 瑞舒伐中间体主链醇的制备方法
CN104059024B (zh) * 2014-06-16 2016-04-06 浙江大学 瑞舒伐他汀中间体的制备方法及中间体化合物
HUE069744T2 (hu) * 2015-01-23 2025-04-28 Centrient Pharmaceuticals Netherlands B V Fejlesztett eljárás a sztatin prekurzor elõállítására
CN104817505A (zh) * 2015-04-23 2015-08-05 南京博优康远生物医药科技有限公司 一种制备n-[4-(4-氟苯基)-5-羟甲基-6-异丙基-嘧啶-2-基]-n-甲基甲磺酰胺的方法
CN109912522B (zh) * 2017-12-12 2021-04-13 北京颖泰嘉和生物科技股份有限公司 制备三唑啉硫酮化合物的方法
CN109081815A (zh) * 2018-11-12 2018-12-25 甘肃农业大学 一种新型亲电试剂甲磺酸嘧啶酯的制备方法
CN111138369A (zh) * 2019-12-17 2020-05-12 上海雅本化学有限公司 瑞舒法他汀中间体的制备方法
CN115397818A (zh) * 2020-03-27 2022-11-25 东亚St株式会社 氨基嘧啶衍生物及其作为芳烃受体调节剂的应用
CN112174898B (zh) * 2020-11-06 2021-05-04 浙江宏元药业股份有限公司 一种连续氧化二氢嘧啶酮制备羟基嘧啶的新方法
CN116217494B (zh) * 2022-12-30 2024-07-26 浙江乐普药业股份有限公司 一种瑞舒伐他汀中间体及其制备方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
US4625039A (en) 1983-12-21 1986-11-25 Sandoz Pharm. Corp. 4-trisubstituted silyl protected hydroxy-6-oxo-tetrahydropyran-2-yl-aldehyde intermediates
US4650890A (en) 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4677211A (en) 1984-06-29 1987-06-30 Sandoz Pharmaceuticals Corp. Preparation of lactones
US4957971A (en) 1986-07-07 1990-09-18 Warner-Lambert Company Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US5102893A (en) 1986-07-07 1992-04-07 Warner-Lambert Company Trans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4808621A (en) 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
DE3739882A1 (de) 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
DE3741508A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Wasserloesliche disazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe
DE3741509A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
GB2244705B (en) 1988-02-18 1992-07-15 Bristol Myers Co Preparation of antihypercholesterolemic tetrazole compounds and intermediates thereof
EP0367895A1 (en) 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
IE914005A1 (en) * 1990-12-14 1992-06-17 Zeneca Ltd Novel intermediates
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
ATE158579T1 (de) 1992-07-02 1997-10-15 Hoechst Ag Verfahren zur herstellung von (3r,5s)6-hydroxy- 3,5-0-isopropyliden-3,5-dihydroxy-hexansäure- tert.-butylester
JP3197971B2 (ja) 1993-03-01 2001-08-13 塩野義製薬株式会社 ５−カルボアルコキシピリミジン誘導体の合成方法
CA2205384C (en) 1994-11-16 2004-06-29 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
DE19517186A1 (de) 1995-05-11 1996-11-14 Bayer Ag Verfahren zur Herstellung substituierter 2-Fluor-pyrimidine
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
US6278001B1 (en) * 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
JP2000501734A (ja) 1995-12-14 2000-02-15 メルク エンド カンパニー インコーポレーテッド ジヒドロピリミジノンの製造方法
WO1999007695A2 (en) 1997-08-05 1999-02-18 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST
EP1055671B1 (en) 1998-12-10 2004-12-01 Kaneka Corporation A process for producing a simvastatin precursor
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
EP1193259A4 (en) 1999-06-23 2003-01-29 Ajinomoto Kk dihydropyrimidine
WO2001004336A1 (de) 1999-07-09 2001-01-18 Forschungszentrum Jülich GmbH Verfahren zur reduktion von keto-carbonsäuren und deren estern
SK285993B6 (sk) 1999-07-13 2008-01-07 Lonza Ag Spôsob výroby derivátov pyrimidínu substituovaných aminoskupinou a ich medziprodukty
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
US8374574B1 (en) 2000-07-06 2013-02-12 Motorola Mobility Llc Method and apparatus for storing a message for playback during a user-initiated emergency telephone call from a wireless device
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
JP2004536813A (ja) 2001-06-06 2004-12-09 ブリストル−マイヤーズ　スクイブ　カンパニー キラルジオールスルホンおよびジヒドロキシ酸ＨＭＧＣｏＡレダクタ−ゼ阻害剤
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
JP2004533479A (ja) 2001-07-06 2004-11-04 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド スタチン誘導体、特に７−アミノ３，５−ジヒドロキシヘプタン酸誘導体及びその中間体の合成に有用な中間体の調製方法
IL159741A0 (en) * 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
IL160043A0 (en) 2001-08-22 2004-06-20 Ciba Sc Holding Ag Process for the preparation of indole derivatives
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
AU2003228010A1 (en) 2002-05-21 2003-12-02 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
SI1578733T1 (sl) 2002-12-10 2011-07-29 Ranbaxy Lab Ltd Postopek za pridobitev rosuvastatina
BR0317313A (pt) 2002-12-16 2005-11-08 Astrazeneca Uk Ltd Processo para a preparação de um composto, e, composto
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
KR20060135712A (ko) 2003-12-24 2006-12-29 테바 파마슈티컬 인더스트리즈 리미티드 높은 ｓｙｎ형 대 ａｎｔｉ형 비율을 지닌 스타틴의 제조방법
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
CN102112817B (zh) 2008-10-29 2014-04-30 三菱电机株式会社 空调装置

Also Published As

Publication number Publication date
JP4359141B2 (ja) 2009-11-04
EP1417180B1 (en) 2006-12-27
IS2399B (is) 2008-09-15
ATE349431T1 (de) 2007-01-15
MXPA04000322A (es) 2005-09-08
MY133579A (en) 2007-11-30
JP2004536849A (ja) 2004-12-09
IS7103A (is) 2004-01-12
CN100349877C (zh) 2007-11-21
US20040176401A1 (en) 2004-09-09
JP5016583B2 (ja) 2012-09-05
CN1301977C (zh) 2007-02-28
JP2009167167A (ja) 2009-07-30
KR100888408B1 (ko) 2009-03-13
US20080058520A1 (en) 2008-03-06
DE60217126D1 (de) 2007-02-08
ES2278032T3 (es) 2007-08-01
AR082864A2 (es) 2013-01-16
US8614320B2 (en) 2013-12-24
EP1417180A1 (en) 2004-05-12
NZ531033A (en) 2005-07-29
CO5560574A2 (es) 2005-09-30
PT1417180E (pt) 2007-03-30
NO326173B1 (no) 2008-10-13
DK1417180T3 (da) 2007-04-10
AU2002318041B2 (en) 2008-01-03
US7304156B2 (en) 2007-12-04
CA2453505C (en) 2011-04-19
US20120277432A1 (en) 2012-11-01
CN1763016A (zh) 2006-04-26
CN1527821A (zh) 2004-09-08
HUP0401248A2 (hu) 2004-10-28
BR0211072A (pt) 2004-12-14
AR034772A1 (es) 2004-03-17
WO2003006439A1 (en) 2003-01-23
IL159741A (en) 2009-06-15
EP1417180A4 (en) 2004-10-27
EG24848A (en) 2010-10-27
DE60217126T2 (de) 2007-10-04
IL159741A0 (en) 2004-06-20
HUP0401248A3 (en) 2004-11-29
CA2453505A1 (en) 2003-01-23
HK1064384A1 (en) 2005-01-28
SI1417180T1 (sl) 2007-04-30
PL366831A1 (en) 2005-02-07
CY1107551T1 (el) 2013-03-13
US20110160455A1 (en) 2011-06-30
KR20040030051A (ko) 2004-04-08
US7816528B2 (en) 2010-10-19
US8222412B2 (en) 2012-07-17

Similar Documents

Publication Publication Date Title
NO20040122L (no) Fremgangsmåte for fremstilling av aminopyrimidinforbindelser samt pyrimidinforbindelser
HUP0400152A3 (en) Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
HUP0500851A3 (en) Process for the preparation of rosuvastatin
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
DE50213202D1 (de) Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
DK3808743T3 (da) HIV-hæmmende pyrimidin-derivater
NO20053115D0 (no) Fremgangsmate for fremstilling av 2'-forgrenede nukleosider.
NO20054404D0 (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
AU2003216592A8 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
NO20034836D0 (no) Sammensmeltede pyrimidiner som antagonister av kortikotropinfrigivelsesfaktoren (CRF)
IL164784A0 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
IL163658A0 (en) Assay for activity of the actriib kinase
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
SI1578731T1 (sl) Postopek za pripravo pirimidinskih spojin
NO20035538D0 (no) Fremgangsmåte for fremstilling av zaleplon
PL351088A1 (en) Process for the preparation of substituted pyrimidines
GB0112802D0 (en) Pyrimidine derivatives
GB0112803D0 (en) Pyrimidine derivatives
PL373627A1 (en) Process for the preparation of melamine
GB0119477D0 (en) Pyrimidine derivatives
NL1019840A1 (nl) Werkwijze voor het bereiden van zeer zuiver metheenamine.
HUP0401846A3 (en) Process for the preparation of (pyrimidin-2-yl)methyl ketones
SI1200414T1 (en) Process for the preparation of substituted pyrimidines
ITMI20000311A0 (it) Processo per la preparazione di eterocicli
GB0112804D0 (en) Pyrimidine derivatives